Results 61 to 70 of about 8,048 (135)

Unusual familial cystic kidney disease: combining fine radiologic and genetic evaluation to solve the case

BMC Nephrology
Background Autosomal dominant polycystic kidney disease (ADPKD) is the most prevalent hereditary kidney disease, characterized by enlarged kidneys with numerous cysts, high blood pressure, and a variety of extrarenal complications.
Sylvain Bodard, Rim Nabbout, Olivier Hélénon, Bertrand Knebelmann   +3 more
doaj   +1 more source

Generation of an induced pluripotent stem cell line (ZSPHARi002-A) from a patient with autosomal dominant polycystic kidney disease carrying a heterozygous PKD1 mutation

Stem Cell Research
Autosomal dominant polycystic kidney disease (ADPKD), a single-gene-inherited kidney disease, is a common cause of end-stage kidney disease (ESKD). The PKD1 gene mutation is the most common cause of ADPKD, accounting for approximately 78% of cases. ADPKD
Yeye Zhang, Ye Chen, Jun Fan, Guangzhao Lu, Qianzhou Lv, Donghui Lao, Xiaoyu Li   +6 more
doaj   +1 more source

The Relationship of Renalase with Diurnal Blood Pressure Rhythm, Left Ventricular Mass Index and Carotid Intima–media Thickness in Autosomal Dominant Polycystic Kidney Disease

Saudi Journal of Kidney Diseases and Transplantation
This study investigated the relationship between renalase and diurnal blood pressure (BP) rhythm, left ventricular mass index (LVMI) and carotid intima-media thickness (IMT) in autosomal dominant polycstic kidney disease (ADPKD) patients.
Veysel Erol, Mevlüt Çeri, Mehmet Mert, Oğuz Kılıç, İsmail Doğu Kılıç, İbrahim Hasbey, Nuran Sabır, Süleyman Demir, Ayşen Kardeşler, Belda Dursun   +9 more
doaj   +1 more source

End Point Selection in ADPKD Clinical Trials

Kidney International Reports
Autosomal dominant polycystic kidney disease (ADPKD) is the leading hereditary cause of kidney failure. Challenges have arisen in developing consensus-based clinical trial end points endorsed by the wider ADPKD research community and regulators.
Kitty St Pierre, Ragada El-Damanawi, Julia Jefferis, David W. Johnson, Carmel M. Hawley, Christine E. Staatz, Andrea K. Viecelli, Andrew J. Mallett   +7 more
doaj   +1 more source

End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases

ClinicoEconomics and Outcomes Research, 2015
Steven M Brunelli,1 Christopher M Blanchette,2,3 Ami J Claxton,1 Debosree Roy,2 Sandro Rossetti,3 Benjamin Gutierrez31DaVita Clinical Research, Minneapolis, MN, USA; 2University of North Carolina, Charlotte, NC, USA; 3Otsuka America Pharmaceutical, Inc.,
Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B   +5 more
doaj  

Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, and Outcomes in Autosomal Dominant Polycystic Kidney Disease

Kidney Medicine
Rationale & Objective: Using OVERTURE (NCT01430494) study data on patient-perceived health, health care utilization, and productivity in autosomal dominant polycystic kidney disease (ADPKD), this research was conducted to characterize the burden of ...
Dorothee Oberdhan, Aaron Yarlas, Jakob B. Bjorner, Holly Krasa   +3 more
doaj   +1 more source

Kidney Volume and Molecular Processes are Dynamic in ADPKD

Kidney International Reports
Introduction: Although progress has been made toward elucidating cellular pathways related to initial cystogenesis in autosomal dominant polycystic kidney disease (ADPKD), the mechanisms that contribute to disease progression and the timing of ...
Ali Tug, Jamie Zheng, Yahya Alsawaf, Jared Lutsic, Athreya Rangavajhula, Nalin Sharma, Youwen Zhang, Ivan Vuckovic, Slobodan Macura, Christian Hanna, Marie C. Hogan, Vicente E. Torres, Peter C. Harris, Alfonso Eirin, Maria V. Irazabal   +14 more
doaj   +1 more source

Incremental health care resource utilization and expenditures associated with autosomal dominant polycystic kidney disease

ClinicoEconomics and Outcomes Research, 2018
Neeraj N Iyer,1 Nicholas J Vendetti,2 Daniel I Levy,3 Jack Mardekian,4 Marko A Mychaskiw,2 Joseph Thomas III1 1Regenstrief Center for Healthcare Engineering and Center for Health Outcomes Research and Policy, College of Pharmacy, Purdue University, West ...
Iyer NN, Vendetti NJ, Levy DI, Mardekian J, Mychaskiw MA, Thomas III J   +5 more
doaj  

Arterial Function Worsens Faster than Renal Function in Autosomal Dominant Polycystic Kidney Disease

Turkish Journal of Nephrology, 2019
OBJECTIVE: Early arterial stiffness has been shown in autosomal dominant polycystic kidney disease (ADPKD) patients with preserved renal function. However, to our knowledge, no prospective study evaluated changes in arterial functions in patients with ...
Abdülmecit YILDIZ, Alparslan ERSOY, Saim SAĞ, Ayşegül ORUÇ, Ercan ÇİĞİLLİ, Yavuz AYAR, Sümeyye GÜLLÜLÜ, Cuma Bülent GÜL   +7 more
doaj  

Canadian Society of Nephrology Commentary on the 2025 Kidney Disease Improving Global Outcomes Clinical Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease. [PDF]

Can J Kidney Health Dis
Lanktree MB, Ashawasega N, Bevilacqua M, Bichet DG, Bollée G, Brown PA, Girard L, Goodyer P, Hingwala J, Lemaire M, McFarlane P, Moist L, Pei Y, Proulx N, Schott C, Soroka S, Vlasschaert C, Watkins N, Alam A.   +18 more
europepmc   +1 more source